Empagliflozin reduces hospitalisation risk for heart-failure and cardiovascular death by 21 per cent, shows Boehringer Ingelheim’s Emperor-Preserved trial Read more
Epygenix Therapeutics announces FDA acceptance of IND to initiate clinical trial of EPX-100 to treat LGS Read more
Sun Pharma and Cassiopea announce expiry of HSR Act process and consummation of Winlevi agreement Read more